The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; Ionctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche/Genentech; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; BioAtla; Blueprint Medicines; CytomX Therapeutics; Genmab; GlaxoSmithKline; Ipsen; Kelun; Novartis; Pfizer; Spectrum Pharmaceuticals; Symphogen; Takeda/Millennium; Tocagen
Travel, Accommodations, Expenses - Cancer Core Europe; Department of Defense; ESMO; Huntsman Cancer Institute; Karolinska Cancer Institute; King Abdullah International Medical Research Center; Louisiana State University; Molecular Partners
Other Relationship - Chinese University of Hong Kong; Elsevier; European Journal of Cancer; GlaxoSmithKline; SOLTI; Vall d'Hebron University Hospital Institute of Oncology
 
Cesar Augusto Perez
Consulting or Advisory Role - Regeneron
 
Kit Man Wong
No Relationships to Disclose
 
Michael L. Maitland
Consulting or Advisory Role - Acceleron Pharma (I); Actelion/Janssen (I); Gossamer Bio (I); Reata Pharmaceuticals (I); United Therapeutics (I)
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
 
Frank Tsai
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Abbvie; Bayer Health; Celgene; Clovis Oncology; Cornerstone Pharmaceuticals; EMD Serono; ipsen; qed therapeutics
Research Funding - Abbvie (Inst); Bayer (Inst); boston biomedical (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); pfizer (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; boston Biomedical; EMD Serono
Other Relationship - novocure; Pancreatic Cancer Action Network
 
Kai Hsin Liao
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
I-Ming Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Lada Markovtsova
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Ira A Jacobs
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nora Cavazos
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Meng Li
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Consulting or Advisory Role - AbbVie (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunomet (Inst); Mekanistic Therapeutics (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ryvu Therapeutics (Inst); Sotio (Inst); Trillium Therapeutics (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen